Mizuki Hino

Dr. Mizuki Hino

Tohoku Univ.
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Neuron
Verified
Journal Article
Closed access
KSKaoru Seiriki
Kaoru Seiriki
AKAtsushi Kasai
Atsushi Kasai
THTakeshi Hashimoto
Takeshi Hashimoto
WSWiebke Schulze
Wiebke Schulze
MNMisaki Niu
Misaki Niu
HHHitoshi Hashimoto
Hitoshi Hashimoto

1 April 2000 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MHMizuki Hino
Mizuki Hino
KKKazuki Kurogi
Kazuki Kurogi
MOMasa-Aki Okubo
Masa-Aki Okubo
MMMaki Murata-Hori
Maki Murata-Hori
HHHiroshi Hosoya
Hiroshi Hosoya

1 July 2019 in EBioMedicine
Verified
Journal Article
Open access
TOTetsuo Ohnishi
Tetsuo Ohnishi
SBShabeesh Balan
Shabeesh Balan
MTManabu Toyoshima
Manabu Toyoshima
MMMotoko Maekawa
Motoko Maekawa
HOHisako Ohba
Hisako Ohba
TYTakeo Yoshikawa
Takeo Yoshikawa
Betaine is known to act against various biological stresses and its levels were reported to be decreased in schizophrenia patients. We aimed to test the role of betaine in schizophrenia pathophysiology, and to evaluate its potential as a novel psychotherapeutic. Using Chdh (a gene for betaine synthesis)-deficient mice and betaine-supplemented inbred mice, we assessed the role of betaine in psychiatric pathophysiology, and its potential as a novel psychotherapeutic, by leveraging metabolomics, behavioral-, transcriptomics and DNA methylation analyses. The Chdh-deficient mice revealed remnants of psychiatric behaviors along with schizophrenia-related molecular perturbations in the brain. Betaine supplementation elicited genetic background-dependent improvement in cognitive performance, and suppressed methamphetamine (MAP)-induced behavioral sensitization. Furthermore, betaine rectified the altered antioxidative and proinflammatory responses induced by MAP and in vitro phencyclidine (PCP) treatments. Betaine also showed a prophylactic effect on behavioral abnormality induced by PCP. Notably, betaine levels were decreased in the postmortem brains from schizophrenia, and a coexisting elevated carbonyl stress, a form of oxidative stress, demarcated a subset of schizophrenia with "betaine deficit-oxidative stress pathology". We revealed the decrease of betaine levels in glyoxylase 1 (GLO1)-deficient hiPSCs, which shows elevated carbonyl stress, and the efficacy of betaine in alleviating it, thus supporting a causal link between betaine and oxidative stress conditions. Furthermore, a CHDH variant, rs35518479, was identified as a cis-expression quantitative trait locus (QTL) for CHDH expression in postmortem brains from schizophrenia, allowing genotype-based stratification of schizophrenia patients for betaine efficacy. The present study revealed the role of betaine in psychiatric pathophysiology and underscores the potential benefit of betaine in a subset of schizophrenia. FUND: This study was supported by the Strategic Research Program for Brain Sciences from AMED (Japan Agency for Medical Research and Development) under Grant Numbers JP18dm0107083 and JP19dm0107083 (TY), JP18dm0107129 (MM), JP18dm0107086 (YK), JP18dm0107107 (HY), JP18dm0107104 (AK) and JP19dm0107119 (KH), by the Grant-in-Aid for Scientific Research on Innovative Areas from the MEXT under Grant Numbers JP18H05435 (TY), JP18H05433 (AH.-T), JP18H05428 (AH.-T and TY), and JP16H06277 (HY), and by JSPS KAKENHI under Grant Number JP17H01574 (TY). In addition, this study was supported by the Collaborative Research Project of Brain Research Institute, Niigata University under Grant Numbers 2018-2809 (YK) and RIKEN Epigenetics Presidential Fund (100214-201801063606-340120) (TY).

1 November 2016 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
MHMizuki Hino
Mizuki Hino
YKYasuto Kunii
Yasuto Kunii
JMJunya Matsumoto
Junya Matsumoto
AWAkira Wada
Akira Wada
ANAtsuko Nagaoka
Atsuko Nagaoka
HYHirooki Yabe
Hirooki Yabe

16 October 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
KNKeisuke Nishiura
Keisuke Nishiura
NINaoki Ichikawa-Tomikawa
Naoki Ichikawa-Tomikawa
Kotaro SugimotoKotaro Sugimoto
Kotaro Sugimoto
YKYasuto Kunii
Yasuto Kunii
KKKorehito Kashiwagi
Korehito Kashiwagi
Hideki ChibaHideki Chiba
Hideki Chiba
Schizophrenia is thought to be caused by a combination of genetic and environmental factors; however, its pathogenesis remains largely unknown. Here, we focus on the endothelial tight-junction protein claudin-5 (CLDN5), because the CLDN5 gene is mapped to the schizophrenia-associated 22q11.2 deletion region, and a single nucleotide polymorphism in the CLDN5 locus is also linked to schizophrenia. We show, by RT-qPCR and immunohistochemistry, that the expressions of CLDN5 mRNA and protein are significantly increased and decreased, respectively, in the schizophrenic prefrontal cortex (PFC) compared with control PFC. These changes were not observed in the schizophrenic visual cortex (VC), and neither the density nor diameter of the CD34-positive microvessels was altered in the schizophrenic PFC or VC. Interestingly, protein kinase A (PKA) was activated in the microvascular and perivascular regions of the schizophrenic PFC, and the pPKA-positive microvascular endothelial cells occasionally exhibited focal loss of CLND5. Since we previously demonstrated that cAMP induced CLDN5 mRNA expression and size-selective loosening of the endothelial barrier in PKA-independent and -dependent manners, respectively, a similar mechanism could contribute to the discrepancy between mRNA and protein expression of CLDN5 in the schizophrenic PFC. Taken collectively, these findings provide novel insights into the pathophysiology of schizophrenia.

1 March 2017 in Journal of Proteomics
Verified
Journal Article
Closed access
MHMio Hirayama-Kurogi
Mio Hirayama-Kurogi
YTYohei Takizawa
Yohei Takizawa
YKYasuto Kunii
Yasuto Kunii
JMJunya Matsumoto
Junya Matsumoto
AWAkira Wada
Akira Wada
SOSumio Ohtsuki
Sumio Ohtsuki